Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

14 February 2024 : Review article  

Clinical Performance of Glass Ionomer Cement in Load-Bearing Restorations: A Systematic Review

Laura Durrant ORCID logo1ABCDEF, Mahdi Mutahar ORCID logo1BCDEF*, Arwa A. Daghrery ORCID logo2DFG, Nassreen H. Albar ORCID logo2DFG, Ghadeer Saleh Alwadai ORCID logo3EG, Saleh Ali Alqahtani ORCID logo4DG, Laila Adel Al Dehailan ORCID logo5DEG, Naif Nabel Abogazalah ORCID logo4CG, Nada Ahmad Alamoudi ORCID logo6DG, Mohammed M. Al Moaleem ORCID logo7CFG

DOI: 10.12659/MSM.943489

Med Sci Monit 2024; 30:e943489

Authors information Article notes Copyright and License information

Table 4 Characteristics of the studies during different recall periods and their relation to esthetics, functions, and biological behavior (n=12).

Materials used3-month6-month9-month12-month2-year3-year4-year5-year6-year10-yearAuthors
EQUIATetric EvoCeram/NAp>0.05/NAp>0.05NAp>0.05/////Uzel et al, 2022 []42
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///NAp>0.05/7.7% 25.3% 27.9% 22.6% 2/5.4% 22.6% 27.9% 25.1% 2//Wafaie et al, 2023 []43
EQUIAFiltek Z550SonicFilX-tra FilNAp>0.055.88% 23.12% 22.94% 22.94% 211.76% 26.75% 25.88% 25.88% 2///////Akman and Tosun 2020 []44
EQUIA FilGradia Direct Posterior///NAp>0.05/NAp>0.05NAp>0.05/NAp>0.05NAp>0.05Gurgan et al, 2020 []45
EQUIA FilZ350-3M/NAp>0.05/NAp>0.05NAp>0.05/////Menezes-Silva et al, 2020 []46
EQUIAAmelogen PlusNAp>0.05NAp>0.05NAp>0.05///////Kharma et al, 2018 []47
EQUIATetric EvoCeram/NAp>0.05/NAp>0.05NAp>0.05/////Uzel et al, 2022 []42
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///85% 215% 370% 230% 362.5%2 37.5% 310% 2/84.6% 215.4% 381.6% 218.4% 373.7% 226.3% 310.3% 2/100% 284.2% 215.8% 378.9% 221.1% 315.4% 2//Wafai et al, 2023 []43
EQUIAFiltek Z550SonicFilX-tra FilNAp>0.05NAp>0.05NAp>0.05///////Akman and Tosun, 2020 []44
EQUIA FilGradia Direct Posterior///NAp>0.05/2.6% 2100% 12.1% 2100% 1/14.3% 213.7% 213.4% 2(15.8% 2)4% 2(2.6% 2)Gurgan et al, 2020 []45
EQUIA FilZ350-3M/56.6% 228.6% 2/NAp>0.05NAp>0.05/////Menezes-Silva et al, 2020 []46
EQUIAAmelogen PlusNAp>0.05NAp>0.05NAp>0.05///////Kharma et al, 2018 []47
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///NA>0.05/NA>0.05/8.1% 25.4% 313.2% 27.9% 313.2% 27.9% 35.1% 2//Wafaie et al, 2023 []43
EQUIAFiltek Z550SonicFilX-tra FilNA>0.05NA>0.05/NA>0.05//////Akman and Tosun, 2020 []44
EQUIA FilGradia Direct Posterior///NA>0.05/NA>0.05NA>0.05/NA>0.05NA>0.05Gurgan et al, 2020 []45
EQUIA FilZ350-3M/43.4% 29.1% 2/32.4% 210.8% 246.8% 215.2% 2/////Menezes-Silva et al, 2020 []46
EQUIATetric EvoCeram/NAp>0.05/94.286%100%97.1%100%/////Uzel et al, 2022 []42
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///92.587.590%95%/89.7%87.2%89.7%92.3%/89.7%89.5%88.6%92.3%//Wafaie et al, 2023 []43
EQUIAFiltek Z550SonicFilX-tra Fil97.06%100%100%100%88.24%100%100%100%/82.35%100%100%100%//////Akman and Tosun, 2020 []44
EQUIA FilFuji IX GP Fast////////86.5%86.8%/Heck et al, 2020 []52
EQUIA FilFiltek Z250////97%98.5%/////Molina et al, 2020 []51
EQUIA FilZ350-3M/98.7%100%/95.8%98.7%90.3%91.5%/////Menezes-Silva et al, 2020 []46
EQUIA ForteStainless Steel Crown (Hall Technique)/////35%82%////Araujo et al, 2020 []48
EQUIA FilGradia Direct Posterior///NAp>0.05/96.1% (100%)100% (100%)96% (100%)100% (100%)/NAp>0.05NAp>0.05Gurgan et al, 2020 []45
EQUIAFuji IX GP Fast///100%93.1%94.6%93.9%86.2%74%////Fotiadou et al, 2019 []41
EQUIAFiltek P60/////82.9%95.1%////Kupietzky et al, 2019 []50
VitremerFiltek Z250///98%96%74%74%/////Dermata et al, 2018 []49
EQUIAFuji IX GP Fast///NAp>0.05NAp>0.05NAp>0.05////Fotiadou et al, 2019 []41
EQUIATetric EvoCeram/NAp>0.05/NAp>0.05NAp>0.05/////Uzel et al, 2022 []42
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///NAp>0.05/NAp>0.05/NAp>0.05//Wafaie et al, 2023 []43
VitremerFiltek Z250///NAp>0.0512% 24% 52% 5/////Dermata et al, 2018 []49
EQUIAFiltek P60/////NAp>0.05////Kupietzky et al, 2019 []50
EQUIA FilZ350-3M/NAp>0.05/NAp>0.05NAp>0.05/////Menezes-Silva et al, 2020 []46
EQUIATetric EvoCeram/NAp>0.05/NAp>0.05NAp>0.05/////Uzel et al, 2022 []42
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///NAp>0.05/NAp>0.05/NAp>0.05//Wafaie et al, 2023 []43
EQUIAFiltek Z550SonicFilX-tra FilNAp>0.05NAp>0.05/NAp>0.05//////Akman and Tosun, 2020 []44
EQUIA FilFuji IX GP Fast////////NAp>0.05/Heck et al, 202 []52
EQUIA FilGradia Direct Posterior///NAp>0.05/NAp>0.05NAp>0.05/NAp>0.05NAp>0.05Gurgan et al, 2020 []45
EQUIAFuji IX GP Fast///NAp>0.05NAp>0.05NAp>0.05////Fotiadou et al, 2019 []41
EQUIAAmelogen PlusNAp>0.05NAp>0.05NAp>0.05///////Kharma et al, 2018 []47
EQUIATetric EvoCeram/NAp>0.05/NAp>0.05NAp>0.05/////Uzel et al, 2022 []42
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///NAp>0.05/NAp>0.05/NAp>0.05//Wafaie et al, 2023 []43
EQUIAFiltek Z550SonicFilX-tra FilNAp>0.05NAp>0.05/NAp>0.05//////Akman and Tosun, 2020 []44
EQUIA FilFuji IX GP Fast////////NAp>0.05/Heck et al, 2020 []52
EQUIA FilGradia Direct Posterior///NAp>0.05/NAp>0.05NAp>0.05/NAp>0.05NAp>0.05Gurgan et al, 2020 []45
EQUIA ForteStainless Steel Crown (Hall Technique)/////NAp>0.05////Araujo et al, 2020 []48
EQUIAFiltek P60/////NAp>0.05////Kupietzky et al, 2019 []50
EQUIAFuji IX GP Fast///NAp>0.05NAp>0.05NAp>0.05////Fotiadou et al, 2019 []41
VitremerFiltek Z250///NAp>0.05NAp>0.05/////Dermata et al, 2018 []49
EQUIAAmelogen PlusNAp>0.05NAp>0.05NAp>0.05///////Kharma et al, 2018 []47
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///NAp>0.05/NAp>0.05/NAp>0.05//Wafaie et al, 2023 []43
EQUIA FilFuji IX GP Fast////////NAp>0.05/Heck et al, 2020 []52
EQUIAFuji IX GP Fast///NAp>0.05NAp>0.05NAp>0.05////Fotiadou et al, 2019 []41
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///NAp>0.05/NAp>0.05/NAp>0.05//Wafaie et al, 2023 []43
VitremerFiltek Z250///100% 115% 26% 226% 2/////Dermata et al, 2018 []49
EQUIATetric EvoCeram/100% 1100% 1/5.71% 2100% 125.71% 25.17% 38.57% 2////Uzel et al, 2022 []42
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250///85% 295% 25% 390% 210% 312.5% 2/97.4% 22.6% 392.1% 27.9% 389.5% 210.5% 317.9% 297.3% 22.7% 386.8% 213.2% 386.8% 213.2% 320.5% 22.6% 3//Wafaie et al, 2023 []43
EQUIA FilFuji IX GP Fast///////100% 290% 210% 3/Heck et al, 2020 []52
EQUIA FilGradia Direct Posterior///NAp>0.05/NAp>0.05/NAp>0.05NAp>0.05Gurgan et al, 2020 []45
EQUIA FilZ350-3M/44.7% 218.2% 2/54.9% 224.3% 248.4% 227.3% 2////Menezes-Silva et al, 2020 []46
EQUIAFuji IX GP Fast///87.5% 296.5% 291.4% 25.71% 393.9% 26.06% 392.3% 23.84% 387.5% 24.16% 3///Fotiadou et al, 2019 []41
EQUIAAmelogen Plus5% 2100% 130% 210% 230% 210% 2//////Kharma et al, 2018 []47
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250/NAp>0.05/NA p>0.052.7% 25.4% 35.3% 25.3% 37.9% 22.6% 35.1% 22.6% 3//Wafaie et al, 2023 []43
EQUIAFiltek Z550SonicFilX-tra Fil11.76% 2100% 1100% 1100% 114.71% 22.94% 3100% 1100% 1100% 1/////Akman and Tosun, 2020 []44
EQUIA FilFuji IX GP Fast/////10% 215% 35% 45% 59.5% 24.8% 3 4.8% 414.3% 5/Heck et al, 2020 []52
EQUIA FilGradia Direct Posterior/NAp>0.05/NAp>0.05/NAp>0.05NAp>0.05Gurgan et al, 2020 []45
EQUIAFuji IX GP Fast/NAp>0.05NAp>0.053.4% 23.4% 310.3% 58.3% 24.2% 44.2% 5///Fotiadou et al, 2019 []41
EQUIAAmelogen PlusNAp>0.05NAp>0.05NAp>0.05////Kharma et al, 2018 []47
EQUIAFiltek Z550SonicFilX-tra FilNAp>0.05NAp>0.05NAp>0.05///Akman and Tosun, 2020 []44
EQUIAFuji IX GP Fast//NAp>0.05NAp>0.05NAp>0.05/Fotiadou et al, 2019 []41
EQUIA ForteStainless Steel Crown (Hall Technique)////4.5% 323.4% 3/Araujo et al, 2020 []48
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250//5% 27.5% 22.5% 35% 22.5% 35% 2/5.1% 37.7% 22.6% 55.1% 22.6% 55.1% 22.6% 22.6% 35.1% 52.6% 25.3% 32.6% 55.3% 35.1% 2Wafaie et al, 2023 []43
EQUIA FilFuji IX GP Fast////25% 25.6% 25.6% 3Heck et al, |2020 []52
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z25025.5% 215% 22.5% 320% 22.5% 2/10.3% 25.1% 313.2%% 210.5% 313.2% 27.9% 37.7% 210.8% 28.1% 318.4% 213.2% 315.8% 210.5% 310.3% 2/Wafaie et al, 2023 []43
VitremerFiltek Z250NAp>0.0522% 22% 3100% 1///Dermata et al, 2018 []49
EQUIAFiltek P60//6.9% 294.8% 351% 3//Kupietzky et al, 2019 []50
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250NAp>0.05NAp>0.052.6% 25.1% 35.3% 22.6% 35.3% 22.6% 35.1% 22.6% 3Wafaie et al 2023 []43
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250NAp>0.05NAp>0.05NAp>0.05Wafaie et al, 2023 []43
EQUIARiva Self Cure (HV)Ketac Universal AplicapFiltek Z250NAp>0.05NAp>0.05NAp>0.05Wafaie et al, 2023 []43
NA – non-significant. Retention success rate% displayed. Class II and Mixed are outside of parenthesis (). Class I results are within parenthesis ().
Back to the Article

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750